K-Glim-M 2mg Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, resulting in reduced blood glucose levels. The combination of these two agents provides complementary mechanisms of action, making K-Glim-M effective for patients inadequately controlled by diet and exercise alone or monotherapy. It is recommended to be used alongside lifestyle modifications such as diet and physical activity. The extended-release formulation ensures a sustained therapeutic effect with improved patient compliance and reduced gastrointestinal side effects commonly associated with Metformin. K-Glim-M should be administered under medical supervision, with regular monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia, lactic acidosis, or gastrointestinal disturbances. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Dose adjustments may be necessary based on patient response and tolerability.